Background. Recent pharmacokinetic/pharmacodynamic (PK/PD) evaluations find that higher oseltamivir exposures may reduce duration of viral shedding and symptoms. However, the impact of such findings on pandemic planning decisions and use of stockpiles has not been described. This study explored the economic impact of oseltamivir dose optimization in supporting pandemic influenza planning decisions in the US.
Background. Recent pharmacokinetic/pharmacodynamic (PK/PD) evaluations find that higher oseltamivir exposures may reduce duration of viral shedding and symptoms. However, the impact of such findings on pandemic planning decisions and use of stockpiles has not been described. This study explored the economic impact of oseltamivir dose optimization in supporting pandemic influenza planning decisions in the US.
Methods. We simulated the infected population across a 1 year seasonal influenza outbreak using a health economic model linked to a PK/PD-epidemiology model (SEIR). Different scenarios were considered to evaluate the cost-effectiveness of high dose (150mg BID) vs standard dose (75mg BID) oseltamivir, low and high virulence, varying transmissibility (low and high attack rates (37% and 67.5% respectively)) and drug uptake (25%, 50%, and 80%). The analysis was conducted from a societal perspective, incorporating both direct and indirect costs. Disease epidemiology and costs were US-specific. Sensitivity analyses were performed to test model robustness.
Results. Results for incremental cost, deaths averted, quality-adjusted life-years (QALY) gained, and incremental cost-effectiveness ratios (ICERs) for high dose compared with standard dose oseltamivir under different scenarios are given in the 
